Triple Negative Breast Cancer News and Research

RSS

Researchers examine the role of two genes that cause triple-negative breast cancer

Researchers at Tulane University School of Medicine identified a gene that causes an aggressive form of breast cancer to rapidly grow.

3 Jun 2020

Novel biomarkers linked to improved outcomes with immunotherapy in metastatic breast cancer

Two novel biomarkers have been found to correlate with improved outcomes with immunotherapy in metastatic breast cancer and may help to identify the patients most likely to benefit from this treatment, according to exploratory studies reported at the ESMO Breast Cancer Virtual Meeting 2020.

22 May 2020

SWOG scientists to deliver online presentations at ASCO20 Virtual Scientific Program

Researchers from SWOG, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, will make 31 presentations as part of the ASCO20 Virtual Scientific Program, the online annual meeting of the American Society of Clinical Oncology (ASCO), which runs May 29-31.

19 May 2020

Indiana researchers identify new target for colorectal cancer immunotherapy

Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified a target for colorectal cancer immunotherapy.

11 May 2020

Talazoparib did not show overall survival benefit in patients with advanced BRCA-mutated breast cancer

New data from the Phase III EMBRACA trial led by researchers at The University of Texas MD Anderson Cancer Center found the PARP inhibitor talazoparib did not demonstrate a statistically significant overall survival (OS) benefit for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.

27 Apr 2020

Technologies converge on interacting surfaces in protein complexes

Researchers have fine-tuned a method to pinpoint surfaces within interacting large multi-protein complexes.

14 Apr 2020

Study provides new evidence about optimal way to treat BRCA carriers with breast cancer

Commonly known as the breast cancer genes, the BRCA gene family plays a role in repairing damaged DNA. Inherited mutations in the genes BRCA1 or BRCA2 raise the risk of developing breast, ovarian, prostate and other cancers.

5 Mar 2020

Inflammation caused by radiation can promote survival of triple-negative breast cancer cells

While radiation is successfully used to treat breast cancer by killing cancer cells, inflammation caused as a side-effect of radiation can have a contrary effect by promoting the survival of triple-negative breast cancer cells, according to research published online in the International Journal of Radiation Biology by Jennifer Sims-Mourtada, Ph.D., director of Translational Breast Cancer Research at ChristianaCare's Helen F. Graham Cancer Center & Research Institute.

24 Feb 2020

Study suggests potential therapy option for early-stage breast cancer

Radionuclide therapy has proven successful in delaying the growth of disseminated tumor cells (DTCs) in early-stage breast cancer in a small animal model, suggesting its use as a potential adjuvant therapy for retarding the proliferation of DTCs.

5 Feb 2020

IU researchers discover how to predict recurrence of triple negative breast cancer

Indiana University School of Medicine researchers have discovered how to predict whether triple negative breast cancer will recur, and which women are likely to remain disease-free.

13 Dec 2019

New drug combo promises help for triple negative breast cancer patients

A new preclinical study on triple negative breast cancer (TNBC) reports that an experimental polo-like kinase 1 (PLK1) inhibitor shrank tumor four times more powerfully when used along with standard drugs than alone. The study, reported in the journal PLOS ONE, opens up a new door of opportunity for patients with this disease.

11 Dec 2019

Combination regimen shows promising results in preclinical models of triple negative breast cancer

Tumor volume in a preclinical model of triple negative breast cancer (TNBC) was reduced four times more when an experimental polo-like kinase 1 (PLK1) inhibitor was combined with a standard-of-care chemotherapeutic agent than when the agent was used alone.

10 Dec 2019

Researchers confirm two new prognostic markers for triple negative breast cancer

Physicians who treat patients with triple negative breast cancer have two new ways to predict which patients may benefit most from the well-established post-surgery treatment known as AC chemotherapy, short for adjuvant doxorubicin and cyclophosphamide.

5 Dec 2019

Researchers identify key protein required for therapeutic resistance in aggressive breast cancer

Researchers at the Lady Davis Institute have identified a key protein that is required for resistance to chemotherapy in the most aggressive form of breast cancer. This holds the promise of opening the door to new therapies for overcoming drug resistance.

2 Dec 2019

Promising method to identify aggressive breast cancers that will respond to immunotherapy

University of North Carolina Lineberger Comprehensive Cancer Center researchers have discovered a promising method to identify aggressive breast cancer tumors that will respond to drugs that unleash the immune system against cancer.

14 Nov 2019

Fresh light on why aggressive breast tumors form and how they can be treated

New research presented at the Society for Endocrinology annual conference in Brighton appears to identify novel methods of therapy for an aggressive type of breast cancer as well as uncovering potential causative factors. The focus of the study is to show how common chemicals present in our surroundings are possibly putting women at risk of a type of breast cancer called triple negative breast cancer (TNBC).

12 Nov 2019

CRISPR helps find difficult to detect cancer cells

Immunotherapy is one of the latest and most effective armaments against various types of cancers. Some of the immunotherapy drugs such as PD-1 inhibitor Keytruda from Merck can block certain proteins in the cancer cells that can make the cells invisible to the immune system normally. Some of the cancers cells can now develop other ways to disguise themselves from being killed by the immune system.

15 Oct 2019